
    
      The planned sample size of 15 participants per treatment group is in keeping with other Phase
      II trials of this type and accounts for the possibility of up to 3 drop-outs per arm, which
      based on previous studies of this type conducted at these sites, represents a conservative
      estimate of the expected drop-out rate.
    
  